Swipe Left For English News
香港,
2024年10月16日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）今日宣布，公司荣获《财资》2024年度ESG（环境、社会和治理）企业大奖铂金奖。连续第四年获此殊荣，不仅体现了药明生物对可持续发展的坚定承诺，还充分彰显了公司运用技术创新驱动生物制药行业绿色高效发展的成功举措。
作为国际权威财经新闻及商业研究机构，《财资》在其年度ESG企业大奖中，从公司治理、可持续融资、能源消耗和温室气体排放、废弃物和水资源管理等多个维度，对企业的ESG表现进行全面评估。药明生物是今年医疗健康行业唯一获此殊荣的公司。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸能够连续第四年获得该奖项。这一奖项不仅是对药明生物近年来在可持续发展领域所取得成就的认可与肯定，更是激励我们深耕可持续发展战略的动能。我们将不断突破，引领全球生物药CRDMO行业的发展，携手共创一个更加绿色、健康的未来。
药明生物在联合国可持续发展目标的指导下，沿着可持续发展道路稳步向前。公司签署科学碳目标倡议（SBTi）承诺书，加入联合国全球契约组织（UNGC），以实际行动履行其对企业和社会可持续发展的承诺。
此外，公司的战略和举措得到了全球评级机构的广泛认可：在明晟MSCI ESG评级中获得AAA评级；获得国际权威企业可持续发展评估机构EcoVadis授予的“铂金”奖牌；入选明晟MSCI ESG 领导者指数；获评晨星Sustainalytics“行业最高评级”和“区域（亚太）最高评级”企业；跻身CDP水安全“A级榜单”并获得CDP气候变化领导力级别评分A-；入选富时社会责任指数系列（FTSE4Good Index Series）；入选恒生ESG 50指数，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
Hong Kong,
October 16, 2024
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards for the fourth year in a row. The prestigious honor recognizes the company's unwavering commitment to sustainable practices as well as its effective approaches to driving innovation and efficiency through green technology.
As a widely recognized business news and research organization, The Asset evaluates companies regarding their ESG responsibilities for its annual ESG Corporate Awards, reviewing a wide range of metrics, including corporate governance, sustainability financing, supplier codes of conduct, energy consumption and GHG emissions, and waste and water management. WuXi Biologics is the only company in the healthcare industry among this year's winners.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are profoundly pleased to win the Platinum Award for the fourth consecutive year. While we view the award as a celebration of WuXi Biologics' sustainability achievements over the past years, we also see it as an impetus for us to persist further in our sustainability efforts, pushing the boundaries and demonstrating our leadership in the biologics CRDMO industry for a greener and healthier future.
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. Demonstrating its commitment, the company is a signatory to the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi) commitment letter.
The company's efforts have been recognized by major ESG rating agencies. It was granted an "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; included in the DJSI World Index and Emerging Markets Index; named to the MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; named a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
